Brought to you by 
Anthera gets inflammation program from Lilly and Shionogi
21 Sep 2006
Executive Summary
Anthera Pharmaceuticals (therapeutics for inflammatory diseases) has licensed worldwide development and commercialization rights (excluding Japan) to a pipeline of preclinical and clinical anti-inflammatory compounds developed by Eli Lilly and Shionogi under a previous agreement. Anthera provided the pharma companies with an undisclosed sum of Anthera equity.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Anthera gets inflammation program from Lilly and Shionogi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice